TW200811225A - Polymer conjugate of podophyllotoxin - Google Patents
Polymer conjugate of podophyllotoxin Download PDFInfo
- Publication number
- TW200811225A TW200811225A TW096117516A TW96117516A TW200811225A TW 200811225 A TW200811225 A TW 200811225A TW 096117516 A TW096117516 A TW 096117516A TW 96117516 A TW96117516 A TW 96117516A TW 200811225 A TW200811225 A TW 200811225A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- podophyllotoxin
- polymer
- integer
- compound
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 96
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 title claims abstract description 77
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 229960001237 podophyllotoxin Drugs 0.000 title claims abstract description 67
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 23
- 229920000805 Polyaspartic acid Polymers 0.000 claims abstract description 22
- 108010064470 polyaspartate Proteins 0.000 claims abstract description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 239000001384 succinic acid Substances 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000003827 glycol group Chemical group 0.000 claims description 20
- 229920001400 block copolymer Polymers 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 239000003053 toxin Substances 0.000 claims description 11
- 231100000765 toxin Toxicity 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 239000002795 scorpion venom Substances 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 241000239226 Scorpiones Species 0.000 claims description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 claims 1
- 239000010103 Podophyllin Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229940068582 podophyllin Drugs 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 17
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 239000003600 podophyllotoxin derivative Substances 0.000 abstract 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 18
- 229940125782 compound 2 Drugs 0.000 description 18
- 229960005420 etoposide Drugs 0.000 description 17
- 229940125904 compound 1 Drugs 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- -1 monoterpene ester Chemical group 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 235000003704 aspartic acid Nutrition 0.000 description 12
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 229940126214 compound 3 Drugs 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N 1,3-di(propan-2-yl)urea Chemical group CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 4
- ZBALFGIGLVIXBV-UHFFFAOYSA-N azane;butanedioic acid Chemical group [NH4+].OC(=O)CCC([O-])=O ZBALFGIGLVIXBV-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 229920002643 polyglutamic acid Polymers 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940093181 glucose injection Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 150000002009 diols Chemical group 0.000 description 2
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- QWLQTDXXEZQUBB-UHFFFAOYSA-N 1,2-di(propan-2-yl)hydrazine Chemical compound CC(C)NNC(C)C QWLQTDXXEZQUBB-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical group NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 1
- 125000003836 4-phenylbutoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- GUJDUXMBBAOBHN-UHFFFAOYSA-N 6-(dimethylamino)-n-(2h-tetrazol-5-yl)pyrazine-2-carboxamide Chemical compound CN(C)C1=CN=CC(C(=O)NC2=NNN=N2)=N1 GUJDUXMBBAOBHN-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- 101100005766 Caenorhabditis elegans cdf-1 gene Proteins 0.000 description 1
- 101100438971 Caenorhabditis elegans mat-1 gene Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical compound [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical group OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 description 1
- RXAXTTGJEMODPY-CJNLAGEVSA-N Leucoside Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O)CO)C(C(C1=C(O)C=C(O)C=C1O1)=O)=C1C1=CC=C(O)C=C1 RXAXTTGJEMODPY-CJNLAGEVSA-N 0.000 description 1
- RXAXTTGJEMODPY-UHFFFAOYSA-N Leucoside Natural products O1CC(O)C(O)C(O)C1OC1C(O)C(O)C(CO)OC1OC(C(C1=C(O)C=C(O)C=C1O1)=O)=C1C1=CC=C(O)C=C1 RXAXTTGJEMODPY-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241001495452 Podophyllum Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- DDFGTVSLZJLQEV-UHFFFAOYSA-N [C](C1CCCCC1)C1CCCCC1 Chemical compound [C](C1CCCCC1)C1CCCCC1 DDFGTVSLZJLQEV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 150000001507 asparagine derivatives Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000005267 main chain polymer Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- YWWNNLPSZSEZNZ-UHFFFAOYSA-N n,n-dimethyldecan-1-amine Chemical compound CCCCCCCCCCN(C)C YWWNNLPSZSEZNZ-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004888 n-propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000120 polyethyl acrylate Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- JWEBFZPSIPMEFI-UHFFFAOYSA-M sodium acetonitrile hydroxide Chemical compound [OH-].[Na+].CC#N JWEBFZPSIPMEFI-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
- C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
- C08G73/1092—Polysuccinimides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/05—Polymer mixtures characterised by other features containing polymer components which can react with one another
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyamides (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Description
200811225 九、發明說明: 【發明所屬之技術領域】 本發明係關於一種由具有聚乙二醇結構部分及2個以上 丁 一酸單醯胺結構部分之聚合物的羧基與鬼臼毒素類的羥 基進行酯鍵結而成之鬼臼毒素類之高分子結合體、其製造 方法及其用途。 【先前技術】
鬼臼t素係多年生草鬼白屬之Podophyllum 的 根或!的水萃取物中所含有之生理活性物質,已知鬼臼毒 素或其衍生物具有抗癌活性。但是,該等化合物中有許多 係難心於水者,又,為了進一步提高有效性,業者一直在 進行鬼臼t素類之水溶性高分子化衍生物等的研究。 例如,於專利文獻!中,對於結合有聚乙二醇之鬼白毒 素高分子衍生物有域。然,,該鬼臼毒素之高分子衍生 :’結構上於一分子聚乙二醇上僅可結合卜2個鬼臼毒素 分子’其結果是,為了投與有效量的藥劑必須投與大量的 聚合物。 :專利文獻2中,,己載有—將藥劑與形成微胞 Λ4- J^L· ^ ...... W丹笟风微腮且顯开 :生的聚乙二酵與聚天門冬胺酸的嵌段共聚物相結合之 古=專利文獻3中,記載有—成為高分子藥物輸送體 ::载體’其中將疏水性物質與聚乙二醇類和聚酸性 ^ Π Γ段共聚物的側㈣酸結合。於專利文獻4中, 吾樹驗類高分子衍生物,兑中 ”中聚乙二酵類和聚麵 /、聚物的側鏈幾基與喜樹驗類的酸性經基結合 120255.doc 200811225 然而,於專利文獻2〜4中並盔關於龟Λ主主 …關於尾臼f素類結合體之記 載。 [專利文獻1 ]曰本專利特表平1 〇_5〗3】87號公報 [專利文獻2]日本專利第2694923號公報 [專利文獻3]日本專利第3268913號公報 [專利文獻4]國際公開第2〇〇4/39869號案 【發明内容】 [發明所欲解決之問題] 專利文獻1中記載之聚乙二醇類部分與藥劑之結合可被 生物體的水解酶切斷,藉此控制藥劑之輸送及释放。然 而,一般認為,當然生物體之水解酶的種差即使於同—種 中個體差異亦較大,與藥劑的結合之切斷依賴於水解酶, 因此擔心被釋放藥劑之效果會產生個體差異。 於專利文獻2中記載之阿德力黴素(adriamycin)結合體, 其中嵌段共聚物與阿德力黴素(adriamycin)係以醢胺鍵結 合,但醯胺鍵係化學上穩定之鍵結樣式,因此由於水解: 造成的藥劑釋放較慢,其藥效方面存在疑問。 依託泊甙(etoposide)或替尼泊甙(teniposide)等鬼臼毒素 類係有用之抗癌劑,業者正在謀求具有水溶性且抗癌活性 k異之其新穎衍生物。 [解決問題之技術手段] 本發明者們為解決上述問題而進行努力研究,結果發 現’若具有羥基的化合物與具有丁二酸單醯胺結構的 1運仃酯鍵結,則產生伴隨丁二酸單醯胺變為環化結構 120255.doc 200811225 (丁二酸醯亞胺)而具有羥基的化合物易於游離之現象,因 此於製造由具有聚乙二醇結構部分及丁二酸單醯胺結構部 分之聚合物與鬼臼毒素類的羥基進行酯鍵結而成之鬼臼毒 素類之高分子結合體時,該高分子結合體並不依賴於水解 酶而釋放出鬼臼毒素類;且完成本發明。 即,本發明係關於以下(1)〜(10)。 ' (1)一種鬼臼毒素類之高分子結合體,其係由具有聚乙 0 二醇結構部分及2個以上丁二酸單醯胺結構部分之聚合物 的羧基與鬼臼毒素類的羥基進行酯鍵結而成者。 (2) 如上述(1)之鬼臼毒素類之高分子結合體,其中具有 聚乙二醇結構部分及2個以上的丁二酸單醯胺結構部分之 聚合物係後段共聚物。 (3) 如上述(2)之鬼臼毒素類之高分子結合體,其中2個以 上的丁二酸單醯胺結構部分係聚天門冬胺酸。 (4) 如上述(3)之鬼臼毒素類之高分子結合體,其中高分 _ 子結合體係以通式(I) [化1] COzR4
. I R1-0-{CH2CH2〇)|-R2-I{NHCOCH)d-(NHCOCH2CH)^NHCOCH)f- CH2C02R4 CH2C〇R5
CORS C02H
• I -{NHC.〇CH2CH)g-CNHCOCH)h.iNHCQCH2CH)i-tNC〇CH)jJ-NHR3 i;H2C02H C0.CH2 (i) 120255.doc 200811225 [式中,R1表示氫原子或(Cl〜C6)烷基,R2表示連接基, R3表示氫原子或(C1〜G6)醯基,R4表示鬼臼毒素類之羥基 殘基,R5表示選自由(C1〜C30)烷氧基、(C7〜C30)芳烷氧 基、(C1〜C30)烷基胺基、二(C1〜C30)烷基胺基、羧基經保 護的胺基酸及-N(R6)CONH(R7)所組成之群之基,R6、R7 可相同亦可不同,表示(C3〜C6)環狀烷基或可經第三胺基 取代之((:1〜05)烷基,{表示5〜11500之整數,(1、6、;^8、 h、i及j分別獨立表示0〜200之整數,其中d+e表示1〜200之 整數,且d+e+f+g+h+i+j表示3〜200之整數,聚天門冬胺酸 之各構成單位之連接順序為任意]所表示之化合物。 (5) 如上述(4)之鬼臼毒素類之高分子結合體,其中R1為 (C1〜C6)烷基,R2為(C2〜G6)伸烷基,R3為(C1〜C6)醯基、t 為8〜23 00之整數,d、e、f、g、h、i及j分別獨立為0〜100 之整數,其中d+e為1〜100之整數,且d+e+f+g+h+i+j為 6〜1 0 0之整數。 (6) 如上述(5)之鬼臼毒素類之高分子結合體,其中R1為 (C1〜C3)烷基,R2為(C2〜C4)伸烷基,R3為(C1〜C3)醯基,t 為100〜300之整數,d、e、f、g、h、i及j分別獨立為0〜90 之整數,其中d+e為1〜90之整數,且d+e+f+g+h+i+j為 15〜90之整數。 (7) 如上述(1)至(6)中任一項之鬼臼毒素類之高分子結合 體,其中鬼臼毒素類為鬼臼毒素、依託泊戒(etopo side)或 替尼泊戒(teniposide)。 (8) —種鬼臼毒素類之高分子結合體,其係藉由於有機 120255.doc 200811225 >谷劑中’使用脫水縮合杳】將且太· ^將具有聚乙二醇結構部分及2個 以上丁二酸單醯胺結構部公夕取人 稱^刀之聚合物的缓基與鬼臼毒素類 的羥基進行酯鍵結而獲得。 (9)如上述(1)至⑺中任—項之鬼臼毒素類之高分子結體 . 《製1^方法’、中於有機溶劑中,使用脫水縮合劑將具有 ‘ %乙二醇結構部分及2個以上丁二酸單醯胺結構部分之聚 合物的羧基與鬼臼毒素類的羥基進行酯鍵結。 • (1〇) 一種抗癌劑,其係將上述⑴至⑻中任一項之鬼白毒 素類之高分子結合體作為有效成分。 [發明之效果] 本發明之鬼白毒素類之高分子結合體,可不依賴於生物 體的水解酶而釋放藥劑,因而難以受個體差異的影響,可 期待其具有有效之治療效果。 【實施方式】 本發明之鬼臼毒素類之高分子結合體,其特徵在於:由 壽具有聚乙二醇結構部分及2個以上的丁二酸單醯胺結構部 分之聚合物的羧基與鬼臼毒素類的羥基進行酯鍵結而成。 於本發明中,所謂丁二酸單醯胺結構部分,意指 Η N C Ο - C - C - C Ο 2 Η結構,例如可列舉:丁二酸單醯胺 ’ (eHNC〇eCH2-CH2-C02H)或、天門冬胺酸的2個羧酸中的1 個被酿胺化之結構(-11]^(:0-(:11(-:^11 + (:112-(:0211、或者 -HNC0-CH2-CHGNH-)-C02H)等。該等丁二酸單醯胺結構 部分,例如,可如聚天門冬胺酸般構成聚合物的主鏈,或 者可為與由類糊精等聚醇、聚離胺酸等聚胺、除聚天門冬 120255.doc 200811225 胺酸以外的聚羧酸(例如,聚乳酸等)所構成之主鏈聚合物 的官能基相結合者。 至於具有聚乙二醇結構部分及2個以上的丁二酸單醯胺 結構部分之聚合物,可列舉:自主鏈聚合物起聚乙二醇結 構部分與丁二酸單酿胺結構部分以梳狀排列之接枝型聚合 物、或具有聚乙二醇結構部分及丁二酸單醯胺結構部分之 聚合物以直列方式結合之嵌段型聚合物(嵌段共聚物)等。
於2個以上丁二酸單醯胺結構部分為聚天門冬胺酸之情 $時接枝型聚合物中亦包含聚天門冬胺酸的主鏈與聚乙 一知結構部分進行部分結合之聚合物等,嵌段型聚合物中 亦包含聚天門冬胺酸的末端與聚乙二醇結構部分的末端結 合之聚合物等。 至於本發明之鬼臼毒素類之高分子結合體之聚合物中之 聚乙二醇結構部分,可列舉將兩末H單個末端加以修飾 之來乙一私,於將兩末端加以修飾之情形時,其修飾基可 相同亦可不同。至於該修飾基,可列舉可具有取代基之 (Cl C6)烧基。至於可具有取代基之⑹〜叫烧基之烧基, 可列舉下述烧基,較好的是(C1〜C4)烧基,例如甲基、乙 土正丙基、正丁基等。至於可具有取代基之(C1〜C6)烷 基之取代基’例如可列舉:胺基、甲胺基、二甲胺基、乙 胺基、二乙胺基等。 至於聚乙二醇結構部分 車父好的是5 0 0〜1 〇 〇 〇 〇 〇左右 本發明之具有聚乙二醇 之分子量,為300〜500000左右, ’更好的是1000〜50000左右。 結構部分及2個以上丁二酸單醯 120255.doc 200811225 月女結構部分之聚合物之分子量,為500〜600000左右,較好 的是600〜110000左右,更好的是8〇〇〜8〇〇〇〇左右。 再者本务明之所渭分子量,係指以GPC法測定之重量 平均分子量。 於本喬月之鬼臼毋素類之南分子結合體中,與具有聚乙 - %結構部分及2個以上丁二酸單醯胺結構部分之聚合物 相結合之鬼臼毒素類之結合量’相對於總幾基數為 1〜1〇〇/。,較好的是1〜90%,更好的是2〜60%。 :發明之鬼臼毒素類’若係具有羥基且具有抗腫瘤活性 毒素類則無特別限定。至於該鬼臼毒素,例如可列 舉之Γ述式(11)所表^鬼臼毒素、以下述式⑽所表 = 戒或以下述式(IV)所表示之替尼泊武等。鬼臼 ^舉mm之醇性經基、下 $下述式(IV)的糖部分之醇性羥基或苯 ㈣’但其取代位置並無限定。 、 本發明之鬼臼毒素類之高入 6主主』 子、、、口 &體,可列舉:Μ ώ命 臼毋素類的醇性羥基或者务 糟由鬼 者進行結合…體2毋素類的紛性經基中之任-炙、。口體、或者其等之混合物; 素類經由醇性經基與—分子高分子结人體逸者’意臼毒 由紛性經基進行結合者可相互混合。 卩結合者與經 120255.doc -12- 200811225 [化2]
OH
[化3]
• [化 4]
120255.doc -13- 200811225 於本發明中,作為2個以上丁二酸單醯胺結構部分,較 好的是聚天門冬胺酸。 至於本發明之鬼臼毒素類之高分子結合體,較好的是以 上述通式(1)[式中,R1表示氫原子或(C1〜C6)烷基,R2表 示連接基,R3表示氫原子或(C1〜C6)醯基,R4表示鬼臼毒 素類之羥基殘基,r5表示選自由(C1〜C30)烷氧基、 (C7〜C30)芳烷氧基、(C1〜C30)烷基胺基、二(C1〜C30)烷基 胺基、羧基經保護之胺基酸及-N(R6)CONH(R7)所組成之 群之基,R6、R7可相同亦可不同,表示(C3〜C6)環狀烷基 或者可經第三胺基取代之(C1〜C5)烷基,t表示5〜11 500之 整數,d、e、f、g、h、i及j分別獨立表示〇〜200之整數, 其中d+e表示1〜200之整數,且d+e+f+g+h+i+j表示3〜200之 整數’聚天門冬胺酸之各構成單位之連接順序為任意]所 表示之化合物。 至於通式⑴之R1中之(C1〜C6)烷基,為直鏈或分枝鏈 (C1〜C6)烷基,例如可列舉:甲基、乙基、正丙基、異丙 基、正丁基、第三丁基、正戊基、異戊基、正己基等,較 好的是直鏈或分枝鏈(C1〜C4)烷基,特別好的是直鏈或分 枝鏈(C1〜C3)烷基,例如特別好的是甲基、乙基、正丙 基、異丙基,尤其好的是甲基。 至於以通式(I)之R2所表示之連接基,並無特別限定, 可列舉(C2〜C6)伸烷基,較好的是(C2〜C4)伸烷基,例如可 列舉:伸乙基、伸丙基、伸丁基等,特別好的是伸丙基。 至於一般式(I)之R3中之(ci〜C6)醯基,並無特別限定, 120255.doc -14- 200811225 例如可列舉:甲醯基、乙醯基、丙醢基 等,較好的是⑼〜C3)醯基,特別好的是乙醯基/乙㈣ 生=式:1)的R4即鬼臼毒素類的羧基殘基中,至於鬼白 可列舉上述鬼白毒素類;若係具有聚合物的羧酸 縮合劑形成_的經基、且具有抗腫瘤 鬼白毋素類’則無特別限定。至於該“毒素類,
:=可列舉:以上述式(„)所表示之鬼白毒素、以上述式 (^)所表示之依託泊㈣以上述式(IV)所表示之替尼 寺。 从通,⑴之R5,表示選自由(Cl〜C3〇)烧氧基、(ο〜⑶) 芳烧氧基、(C1〜C30)统基胺基、三(cl〜C3〇)燒基胺基、將 羧基保護之胺基酸及-N(R6)c〇NH(R7)所組成之群之基, R6、R7為可被相同或不同的(C3〜G6)環狀烷基或第三胺基 取代之(C1〜C5)烷基。作為通式⑴之R5,於一分子中可相 Π亦了不同,又,於鬼臼毒素類之高分子結合體中所使用 之聚合物中,可為單一聚合物亦可為混合物。 至於該(C1〜C30)烷氧基,可列舉直鏈或分枝鏈之 (C1〜C30)燒氧基,較好的是直鏈或分枝鏈之(Ci〜ci〇)燒氧 基,例如可列舉:甲氧基、乙氧基、正丙氧基、異丙氧 基、正丁氧基、第三丁氧基等,·至於(C7〜C30)芳烷氧基, 可列舉··直鏈或分枝鏈之(C7〜C30)芳烷氧基,較好的是直 鍵或分枝鏈之(C7〜C12)芳烷氧基,例如可列舉4_苯基丁氧 基等。 至於該(C1〜C30)烷基胺基或二(C1〜C30)烷基胺基,可列 120255.doc -15- 200811225 舉直鏈或分枝鏈之(Cl〜C3 0)烷基胺基或二(cl〜C3〇)烷基胺 基’·較好的是直鏈或分枝鏈之(C1〜C20)烷基胺基或二 (C1〜C20)烷基胺基,例如可列舉··甲胺基、乙胺基、正丙 胺基、異丙胺基、正丁胺基、第三丁胺基、二甲胺基、二 乙基胺基、二(正丁基)胺基等。 至於保護該羧基之胺基酸,可列舉於通常肽合成中所使 用之保護羧基之胺基酸,例如可列舉苯丙胺酸苄酯等。
至於通式(I)之R5中之-N(R6)c〇nh(R7)[R6、R7為可相 同亦可不同,表示(C3〜C6)環狀烷基或可經第三胺基取代 (1 C 5)烧基]’並無特別限定,例如可列舉··環已胺基 羰基環己胺基、異丙胺基羰基異丙胺基等。 本發明之以上述通式⑴所表示之鬼白毒素類之高分子結 =體中之2個以上的丁二酸單醯胺結構部分即聚天門冬胺 酸中,有…胺基酸型、P-胺基酸型、環化者等構成單元, 該等構成單元之連接順序並無限定,可為嵌段型亦可為無 規型。 =上述-般式⑴所表示之鬼臼毒素類之高分子結合體中 =聚天門冬胺酸之總天門冬胺酸數’係以d+e+f+g+h+i+j 來表示,例如可自製造嵌段共聚物時所㈣之天門冬胺酸 衍生物的量而求得。該天門冬胺酸數(d+e+f+g+h+i切為 3 200個左右,較好的是6〜1〇〇個左右,特別好的是15〜㈧ 鬼白毒素類所結合的天門冬胺酸數(d+e)相對於總天 冬月女酸數(d+e+f+g+h+i+j)之比例為卜刚。/。,較好的 120255.doc -16· 200811225 3〜90%,更好的 !〜_左右,=:二r冬胺™為 左右。 疋1 1〇0個左右,特別好的是1〜90個 述素類所結合之天門冬胺酸數(d+e),例如,如下 键士 〇心’於進行於有機溶财使鬼μ素類進行醋 鍵、、、口之脫水縮合及虛你 …灸,可由反應液中殘存的未反應之鬼 臼毒素類之量而求出。 —土酉文型(d+f+h)相對於總天門冬胺酸數 +e+f+g+h+i+j)之比例為10〜100%,較好的是20〜100〇/〇 ; β’基酸型(e+g+i)之比例為㈣%,較好的是請%。該 比例’例如可藉由選擇聚天門冬胺酸之保護基之脫保護條 件等而適當改變。 上述通式(I)之t為5〜115〇〇左右之整數,較好的是8~23〇〇 左右之整數,更好的是1〇〇〜3〇〇左右之整數。 本發明之鬼白毒素類之高分子結合體,可於水中形成將 聚乙二醇結構部分作為外殼之微胞。 本發明之鬼臼毒素類之高分子結合體,係藉由於有機溶 劑中,使用脫水縮合劑使具有聚乙二醇結構部分及2個以 上丁二酸單醯胺結構部分之聚合物的羧基與鬼白毒素類的 羥基進行酯鍵結,而獲得;該製造方法亦包含於本發明 中。即,例如以下之製造方法··於溶解兩者的有機溶劑 中,較好的是N,N-二甲基曱醯胺(DmF)、1,3-二甲基·2_咪 峻琳酮(DMI)、Ν-曱基吡咯啶酮(ΝΜΡ)等非質子性極性溶 劑中,於0〜180°C、較好的是5〜50°C下,使用二環己基碳 120255.doc -17- 200811225 化一醯亞胺(DCC)、二異丙基碳化二醯亞胺(DIpc)、丨_乙 基-3-(3-一甲胺基丙基)碳化二醯亞胺鹽酸鹽(臀§<^)、1_乙 氧羰基-2-乙氧基-1,2-二氫喹啉酮(EEDQ)等脫水縮合劑, 將以專利文獻2中記載的方法所製備之聚乙二醇結構部分_ 聚天門冬fe酸之肷段共聚物與根據需要將除進行反應的基 以外的官能加以保護之鬼臼毒素類進行反應。又,於進行 該縮合反應之時,亦可使用N,N-二甲胺基吡啶(DMAp)等 反應助劑。縮合反應後,根據需要進行脫保護,再藉由通 常的分離精製等操作製造鬼臼毒素類之高分子結合體。 又’ R5為-N(R6)CONH(R7)基(R6、R7可相同亦可不同, 表不(C3〜C6)環狀烷基或者可經第三胺基取代之(C1〜C5)烷 基)之鬼臼毒素類之高分子結合體,亦可藉由使用上述碳 化二醯亞胺類作為縮合劑之反應而獲得。 至於將(C1〜C30)烷氧基、(C7〜C3〇)芳烷氧基、(cl〜C3〇) 烷基胺基、二(Cl〜C30)烷基胺基或保護羧基的胺基酸導入 通式(I)之化合物中的R5之方法,可以採用以下方法:使聚 合物的羧基活化後與欲結合量所對應的醇、對應的胺或保 護羧基的胺基酸等於鹼性條件下進行反應之方法,使對應 的醇、對應的胺或保護羧基的胺基酸等活化後與聚合物進 行反應之方法等。於精製聚合物後可以同樣之反應使聚合 物中未反應的羧基再活化,此處可使鬼臼毒素類的羥基縮 合,或者重複使不同的醇、胺等反應而合成具有以的各種 取代基之聚合物,繼而,亦可使鬼臼毒素類縮合。又,於 使鬼臼毒素類縮合後,亦可使(C1〜C3〇)烷氧基、(C7〜C3〇) 120255.doc -18- 200811225 蒡烧氧基、(C1〜C3G)院基胺基、二(C1〜⑶)燒基胺 保護羧基之胺基酸等縮合。 /者 其中,本發明之鬼臼毒素類之高分子結合 不只限定於上述方法。 i&法 =二亦包含將本發明…毒素類之高分子結合 劑、錠劑、散劑等通常使用之劑型 為/射 化時通常使用的藥學上容許之載體,例:::::了製劑 劑、崩散劑、溶劑、賦形劑、可溶化劑、分::劑、潤滑 劑、懸濁化劑、防腐劑、止痛劑、色素、化 較好的是作為注射劑使用,通常,例 、中’ -甲基㈣B各相 Cremophor等或其等之混合液)或者水與該祕一醉、 之混合液等。 ” 冷丨生有機容劑 本發明之鬼G毒素類之高分子結合體之旦 根據患者的性別、年齢、生理狀態、病態二I:然可 ㈣經口投與時,通常成人每i曰投== 〇十)〇.01〜500 mg/m2、較好的是0.1〜250 mg/m2成刀 之投與,係於靜脈内、_ k用注射 [實施例] 腫瘤部)等處進行。 以下,根據實施例更具體地說明本發 限定於該等實施例。 仁本發明並不 實施例1 120255.doc -19- 200811225 化合物1(由分子篁12000的甲氧基聚乙二醇部分及聚合 數為35的聚天門冬胺酸部分所構成之嵌段共聚物與依託泊 甙之結合體;通式(I)之Rl = Me(甲基)、R2=伸丙基、R3 = Ac(乙醯基)、R4=依託泊甙殘基、R5=異丙胺基羰基異 丙胺基,d+e+f+g+h+i+j=35,t= 273)之合成 將依專利文獻3中記載的方法所製備的甲氧基聚乙二醇· 聚天門冬fe酸肷段共聚物(天門冬胺酸的聚合數為3 5,1.8 〇 g)及市售之依託泊甙(700 mg)溶解於DMF (70 ml)中,添加 DMAP (72 mg)、DIPC (1.25 ml),於 25°C 下攪拌 20小時。 於反應液中添加乙醇(105 ml)、乙酸乙酯(105 ml)及二丙醚 (840 ml),於室溫下攪拌12〇分鐘,然後濾取沈析物,以乙 醇/二異丙醚(1/4 (v/v),100 ml)清洗之。將所得沈析物溶 解於乙腈/水(1/1 (v/v),210 ml)中,然後於離子交換樹脂 (The Dow Chemical Company製 DOWEX 50 (H+),15 ml)中 進行通塔’以乙腈/水(1/1 (v/v),ml)進行溶出。於所得 浴出部分中添加水(14〇 mi)再於減壓下將乙腈蒸餾除去, 其後進行冷凍乾燥,藉此獲得化合物1 (2 〇6 g)。 根據使用HPLC(高速液相層析)進行反應液中未反應依託 泊戒夏之計量,化合物i中之依託泊甙含量為16.5% (w/w),d+e相對於d+e+f+g+h+i+j之比例為15%。化合物1 中並未檢出游離之依託泊甙。 可藉由本方法可附加異丙胺基羰基異丙胺基作為,其 存在比係由將化合物丨溶解於重氫氧化鈉/重水/重乙腈者的 H NMR(氫核磁共振光譜)而求出,化合物}中異丙胺基羰 120255.doc -20- 200811225 基異丙胺基於聚天門冬胺酸中所占比例,即f+g相對於 d+e+f+g+h+i+j之比例為19·6%。其他天門冬胺酸係游離羧 酸(h+i)或者環狀結構(j)。 實施例2 化合物2(由與分子量12〇〇〇的甲氧基聚乙二醇部分及聚 - 合數為35之聚天門冬胺酸部分所構成之嵌段共聚物與鬼臼 毒素之結合體:通式(I)之R1 = Me(甲基)、R2 =伸丙基、 φ R3 = Ac(乙醯基)、R4 =鬼臼毒素殘基、R5 =異丙胺基羰 基異丙胺基,d+e+f+g+h+i+j = 35,t= 273)之人成 將依專利文獻3中記載的方法所製備之甲氧基聚乙二醇_ 聚天門冬胺酸嵌段共聚物(天門冬胺酸之聚合數為35, mg)及市售之鬼臼毒素(106 mg)溶解sDMF (5 ml)中,添 加 DMAP (12 mg)、DIPC (〇·16 ml),於 25Λ:下攪拌 2〇小 時。於反應液中添加乙醇(15 ml)及二異丙醚(6〇 m][),於室 溫下攪拌120分鐘,然後濾取沈析物,以乙醇/二丙醚('1/4 • (V/V),10 ml)清洗之。將所得沈析物溶解於乙腈/水(1/1 (Wv)、10 ml)中,然後於離子交換樹脂(The D〇w
Company製DOWEX 5 0 (H+),2·5 ml)中進行通塔,以乙腈/ ‘ 水(1/1 (V/V),5 ml)進行溶出。於所得溶出部分中添加水 , (1〇 m1),於減壓下將乙腈蒸餾除去,其後進行冷凍乾燥, 藉此獲得化合物2 (220 mg)。 根據使用HPLC(高速液相層析)進行反應液中 毒素量之計量,化合物2中…毒素含量為二 (w/w),d+e相對於d+e+f+g+h+i+j之比例為131%。化合物 120255.doc • 21編 200811225 2中並未檢出游離之鬼臼毒素。 可藉由本方法附加異丙胺基羰基異丙胺基作為,其存 在比係由將化合物2溶解於重氫氧化鈉/重水/重乙腈中者的 ^-NMR而求出,化合物2中異丙胺基羰基異丙胺基於聚天 門冬胺酸中所占比例,即f+g相對於d+e+f+g+h+i+j之比例 為15.2%。其他天門冬胺酸係游離羧酸(h+i)或者環狀結構 ⑴。 " 實施例3 化合物3(由分子量12000的甲氧基聚乙二醇部分及聚合 數為33的聚天門冬胺酸部分所構成之嵌段共聚物與鬼臼毒 素之結合體:通式(I)之R1 = Me(甲基)、R2 =伸丙基、R3 =Ac(乙醯基)、R4 =鬼臼毒素殘基、R5 =異丙胺基羰基異 丙胺基或者0-苄基苯基丙胺醯基、d+e+f+g+h+i+j = 33,t =273)之合成 將依專利文獻3中記載的方法所製備的甲氧基聚乙二醇_ 聚天門冬胺酸嵌段共聚物(天門冬胺酸之聚合數為33, 464.4 mg)及市售之鬼臼毒素(1〇〇 mg)溶解於dmf (6 ml) 中,添加 DMAP (12 mg)、DIPC (0·09 ml),於 15°C 下授拌 20小時。繼而,添加苯丙胺酸苄酯鹽酸鹽(36·8 mg)、三乙 胺(〇·〇2 ml)及 DIPC (0.23 ml),於 15°C 下進一步授拌 20小 時,其後於25 °C下進一步攪拌4小時。於反應液中添加乙 酸乙酯(10 ml)、乙醇(10 ml)及二異丙醚(8〇 ml),於室溫下 攪拌30分鐘,然後濾取沈析物,以乙醇/二異丙醚(1/4 (v/v),20 ml)清洗之。將所得沈析物溶解於乙腈/水(1/1 120255.doc -22 - 200811225 (Wv),20 ml)中,然後於離子交換樹脂(The D〇w Chemieal Company製DOWEX 50 (H+),3 ml)中進行通塔,以乙腈/水 (1/1 (v/v),20 ml)進行溶出。於所得溶出部分中添加水(25 ml),於減壓下將乙腈蒸餾除去,其後進行冷凍乾燥,藉 此獲得化合物3 (580 mg)。 根據使用HPLC(高速液相析)進行反應液中未反應鬼臼 毒素量之計量,化合物3中之鬼臼毒素含量為13.7〇/〇 (w/w) ’ d+e相對於d+e+f+g+h+i+j之比例為19%。化合物3 中並未檢出游離之鬼臼毒素。 作為R5之一而導入之〇-苄基苯基丙胺醯基,係將化合物 3於乙腈-氫氧化鈉水溶液於4〇。〇下水解6小時,將溶出的 节醇進行定量而求出,〇-苄基苯基丙胺醯基於聚天門冬胺 酉文中所占比例,即f+g相對於d+e+f+g+h+i+j之比例,對於 〇-苄基苯基丙胺醯基結合者而言為13%。 又,亦將異丙胺基羰基異丙胺基導入作為R5,其存在比 係由將化合物3溶解於重氫氧化鈉/重水/重乙腈中者之ιΗ_ NMR(氫核磁共振光譜)而求出。異丙基胺基幾基異丙胺基 於5^天門冬胺酸中所占比例,即f+g相對於d+e+f+g+h+i+j 之比例,對於異丙基胺基羰基異丙胺基結合者而言為 1 5%。該結果為,R5之總量於聚天門冬胺酸中所占比例, 即f+g相對於d+e+f+g+h+i+j之比例為28%。其他天門冬胺 酸係游離羧酸(h+i)或者環狀結構(j)。 比較例1 比較化合物1(由分子量12000的甲氧基聚乙二醇部分及 120255.doc -23- 200811225 聚合數為23的㈣胺酸部分所構成之鼓段共聚物與依託泊 甙之結合體)之合成 將依特開平5-955號公報中記㈣方法所製備的甲氧基 聚乙二醇-聚麩胺酸嵌段共聚物(21 mg)及市售的依託泊武 (9.6 mg)溶解於 DMF (1 ml)中,添加 DMAp (〇 6 爪幻、Dipc
(〇·〇 1 mi) ’於25t;下授拌20小時。於反應液中添加乙醇 (1.5 ml)、乙酸乙酯(1.5 ml)及二異丙醚(12如),於室溫下 攪拌30分鐘,然後濾取沈析物,以乙醇/二異丙醚 (v/v),2 ml)清洗。將所得沈析物溶解於乙腈/水(Μ (Wv),3 ml)中,然後於離子交換樹脂(The D〇w chemieal
Company製D0WEX 50 (H+)、〇·2 ml)中進行通塔,以乙猜/ 水(1/1 (v/v) ’ 1 ml)進行溶出。於所得溶出部分中添加水〇 ml) ’於減壓下將乙腈蒸餾除去,其後進行冷來乾燥,藉 此獲得比較化合物1 (28.0 mg)。 藉由HPLC測量反應液中未反應依託泊甙的量,比較化 合物1中之依託泊甙含量為23.8% (w/w)。比較化合物J中 並未檢出游離之依託泊甙。 比較例2 比較化合物2(由分子量12000的甲氧基聚乙二醇部分及 聚合數為2 3的聚麩胺酸部分所構成之嵌段共聚物與鬼臼毒 素之結合體)之合成 將依特開平5-955號公報中記載的方法所製備的甲氧基 聚乙二醇-聚麩胺酸嵌段共聚物(52 mg)及市售的鬼臼毒素
(10 mg)溶解於 DMF (1 ml)中,添加 DMAP (2 mg)、DTPC 120255.doc -24· 200811225 (0·03 ml),於25°C下攪拌20小時。於反應液中添加乙醇(3 ml)及二異丙醚(12 ml),於室溫下攪拌30分鐘後濾取沈析 物,以乙醇/二異丙醚(1/4 (v/v),2 ml)清洗之,將所得沈 析物溶解於乙腈/水(1/1 〇/v),3 ml)中,然後於離子交換 樹脂(The Dow Chemical Company製 DOWEX 50 (H+),〇·2
ml)中進行通塔,以乙腈/水(1/1 (v/v),1 ml)進行溶出。於 所得溶出部分中添加水(1 ml),於減壓下將乙腈蒸顧除 去,其後進行冷凍乾燥,藉此獲得比較化合物2 (64.3 mg) 〇 根據使用HPLC進行反應液中的未反應鬼臼毒素量之計 量’比較化合物2中之鬼臼毒素含量為丨6 〇% (w/w)。比較 化合物2中並未檢出游離之鬼臼毒素。 試驗例1 化合物1於非酶存在下之藥劑釋放 將化合物1或比較化合物i以聚合物濃度i mg/ml溶解於 PBS(碟酸緩衝生理食鹽水;pH 71)中,且保溫於37。〇。以 HPLC將自該高分子結合體中釋放的依託泊錢行分離, 利用標準曲線進行定量。由定量值與由高分子結合體的藥 劑含有量所求出的總藥劑量之比示於圖ΐσ 如圖1所表明,本發明之高分子結合體(化合物1),即使 =解酶I可於24小時内釋放85%以上的依託泊#,相對 :不具有丁二酸單醯胺結構部分之比較化合物1,即 ;A j夺亦成乎不釋放依託泊甙。該結果顯示,本發明 *类頁阿分子結合體於非酶存在下具有m藥劑 120255.doc -25- 200811225 釋放性能。 試驗例2 化合物2、3於非酶存在下之藥劑釋放 將化合物2、3或比較化合物2以聚合物濃度為j mg/ml溶 解於PBS(磷酸緩衝生理食鹽水;pH 7.1)中,且保溫於 37°C。以HPLC將自該高分子結合體中釋放的鬼臼毒素進 行分離,利用標準曲線進行定量。定量值與由高分子結合 體的藥劑含有量求出的總藥劑量之比示於圖2。 如圖2所表明,本發明之高分子結合體(化合物2及3)即 使無水解酶於24小時内亦釋放丨〇〜6〇%以上之鬼臼毒素, 相對於此,不具有丁二酸單醯胺結構部分的比較化合物 2,即使於24小時亦幾乎不釋放鬼臼毒素。該結果顯示, 本發明之鬼臼毒素類之高分子結合體於非酶存在下具有優 異之藥劑釋放性能。又,亦顯示可自由地控制藥劑釋放性 能。 試驗例3 化合物1之抗腫瘤作用 將於小白鼠皮下繼代培養的小白鼠大腸癌c〇l〇n 26切成 約2 mm的正方形塊,使用套管針將其移植入雌性cDF1小 白鼠的月側皮下。於腫瘤移植後第7日,於小白鼠尾靜脈 内單次投與本發明之高分子結合體(化合物1}或對照藥(依 託泊甙,ETP)。對照群係不投與藥物之群。化合物1係以 5%葡萄糖注射液將其溶解後使用。Ετρ係將Lastet注射劑 (日本化藥公司製)以5%葡萄糖注射液加以稀釋後使用。投 120255.doc -26· 200811225 與後’使用游標卡尺測量腫瘤之長徑(L mm)及短徑(w mm),藉由(LxW2)/2計算腫瘤體積,作為相對於投與曰的 腫瘤體積之相對腫瘤體積而示於表i。又,將此時之體重 變化作為相對於投與日體重之相對體重而示於表1。 [表1] 0 投與後天數 _ 4 0.86 8 1.69 化合物1 450 mg/kg 相對腫瘤體積 1.00 相對體重 1.00 0.87 0.97 ETP 90 mg/kg 相對腫瘤體積 1.00 U7 3.79 相對體重 1.00 0.87 0.97 對照群 相對腫瘤體積 1.00 5.02 11.59 相對體重 1.00 0.98 0.82 由表1顯示,本發明之高分子結合體,於引起與ETP (90 mg/kg)相同程度體重減少之投與量(45〇 mg/kg)中,具有較 ETP優異之抗癌活性,且成為抗癌劑。 試驗例4化合物2及3之抗腫瘤作用 將於小白鼠皮下繼代培養的小白鼠大腸癌c〇1〇n 26切成 約2 mm的正方形塊,使用套管針將其移植入雌性CDF1小 白鼠的背側皮下。於腫瘤移植後第7天(表2中,投與開始 )將本务月之南分子結合體(化合物2及化合物3 )或對照 藥(鬼臼骨素,POD)投與小白鼠尾靜脈内。化合物2及化合 物3,係將 >谷解於5%葡萄糖注射液中者一次投與。對照群 係不投與藥物之群。P〇D係購自Sigma公司,自投與開'始 日起’ H甲基亞颯及5%葡萄糖注射液稀釋者連續$曰 I20255.doc -27- 200811225 投與。投與後,使用游標卡尺測量腫瘤之長徑(L mm)及短 徑(W mm),藉由(LxW2)/2計算腫瘤體積,作為相對於投與 開始日腫瘤體積之相對腫瘤體積而示於表2。又,將此時 的體重變化作為相對於投與開始日的體重之相對體重而示 於表2。 [表2] 才j 0 1與開始E 3 3後之天凄 5 8 化合物2 一次投與75 mg/kg 相對腫瘤體積 1.00 0.82 0.80 2.24 相對體重 1.00 0.96 0.99 1.00 化合物3 一次投與75 mg/kg 相對腫瘤體積 1.00 1.79 2.05 3.26 相對體重 1.00 0.95 0.98 0.94 POD 連續5日投與15 mg/kg (合計75 mg/kg) 相對腫瘤體積 1.00 1.58 1.79 6.08 相對體重 1.00 1.01 0.96 0.98 對照群 相對腫瘤體積 1.00 3.01 4.38 6.52 相對體重 1.00 0.99 0.97 0.86
由表2顯示,本發明之高分子結合體,於引起與POD (15 mg/kg/日,連續5日投與)相同程度體重減少之投與量(75 mg/kg)中,雖然進行單次投與但具有較POD優異之抗癌活 性,且成為抗癌劑。 【圖式簡單說明】 圖1係表示本發明之化合物1(依託泊甙與嵌段共聚物的 聚天門冬胺酸結合之高分子衍生物)及比較化合物1 (依託泊 甙與嵌段共聚物的聚麩胺酸結合之高分子衍生物)之PBS溶 液(pH 7.1,37°C)中依託泊甙釋放量相對於依託泊甙總結合 量之比例。圖1中,-春·表示本發明之化合物1、-〇-表示比 120255.doc -28- 200811225 較化合物1釋放量之比例。 圖2係表示本發明之化合物2及化合物3(鬼臼毒素與嵌段 共聚物的聚天門冬胺酸結合之高分子衍生物)及比較化合 物2(鬼臼毒素與嵌段共聚物的聚麩胺酸結合之高分子衍生 物)之PBS溶液(pH 7.1,37°c)中鬼臼毒素釋放量相對於鬼 臼毒素總結合量之比例。 ‘ 圖2中,-♦-表示本發明之化合物2,-▲-表示本發明之 • 化合物3,-◊-表示比合物2之釋放量之比例。
120255.doc -29-
Claims (1)
- 200811225 十、申請專利範圍: 1 · 一種鬼臼毒素類之高分子結合體,其係由具有聚乙二醇 結構部分及2個以上丁二酸單醯胺結構部分之聚合物的 羧基與鬼臼毒素類的羥基進行酯鍵結而成者。 2. 如請求項1之鬼臼毒素類之高分子結合體,其中具有聚 乙二醇結構部分及2個以上丁二酸單醯胺結構部分之聚 合物為嵌段共聚物。 3. 如請求項2之鬼臼毒素類之高分子結合體,其中2個以上 丁二酸單醯胺結構部分為聚天門冬胺酸。 4. 如請求項3之鬼臼毒素類之高分子結合體,其中高分子 結合體為以通式(I) [化5] C02R4 R1-O-(CH2CH2〇)rR2-[(NHC0CH)d.(NHCOCH2CH)^NHC〇CH)f- CHaC02R4 CH2COR5COR5 co2h ch2co2h coch2 ⑴ [式中,R1表示氫原子或(Cl〜C6)烷基,R2表示連接基, R3表示氫原子或(C1〜C6)醯基,R4表示鬼臼毒素類之羥 基殘基,R5表示選自由(C1〜C30)烷氧基、(C7〜C30)芳烷 氧基、(C1〜C30)烷基胺基、二(C1〜C30)烷基胺基、羧基 經保護之胺基酸及-N(R6)CONH(R7)所組成之群之基, I20255.doc 200811225 R6、R7可相同亦可不同,表示(C3〜C6)環狀烷基或者可 經第二胺基取代之(C1〜C5)烧基,t表示5〜11500之整數, d、e、f、g、h、i及j分別獨立表示〇〜2〇〇之整數,其中 d+e表示1〜200之整數,且d+e+f+g+h+i+j表示3〜200之整 數,聚天門冬胺酸之各構成單位之連接順序為任意]所表 不之化合物。5·如請求項4之鬼臼毒素類之高分子結合體,其中旧為 (C1〜C6)烷基,R2為(C2〜C6)伸烷基,R3為(C1〜C6)醯 基,t為8〜2300之整數,d、e、f、g、h、i及j分別獨立表 示0〜100之整數,其中d + e為1〜1〇〇之整數,且 d+e + f+g+h+i+j為6〜100之整婁文。 6.如請求項5之鬼臼毒素類之高分子結合體,其中以為 (C1〜C3)烷基,R2為(C2〜C4)伸烷基,R3為(C1〜C3)醯 基’ t為1〇〇〜300之整數’ d、e、f、g、卜⑷分別獨立 為〇〜90之整數,其中d+e為丨〜⑽之整數,且 d+e+f+g+h+i+j為 15〜90之整數。 如明求項1至6中任一項之鬼臼毒素類之高分子結合體, 其中鬼臼毒素類為鬼臼毒素、依託泊武(etGpc)side)或者 替尼泊甙(teniposide)。 8. 一種鬼臼毒素類之高分子結合體,其係藉由於有機溶劑 中’使用脫水縮合劑使具有聚乙二醇結構部分及2個以 上丁 一酸單醯胺結構部分之平人# 1: i t 口物的羧基與鬼臼毒素類 的經基進行酯鍵結而獲得。 9 · 一種如請求項1至7中任一項之舍主 、之鬼臼毋素類之高分子結合 120255.doc 200811225 體之製、it太、、 且有卷 去’其中於有機溶劑中,i用脫水縮合劑使 八Λ乙一知結構部分及2個以上丁二酸單醯胺結構部 7刀之聚合物的m基與鬼臼毒素類的經基進行醋鍵結。 10. 一種抗癌劑,其係以如請求項丨至8中任一項之鬼臼毒素 類之高分子結合體為有效成分。120255.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006138509 | 2006-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200811225A true TW200811225A (en) | 2008-03-01 |
Family
ID=38723224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096117516A TW200811225A (en) | 2006-05-18 | 2007-05-17 | Polymer conjugate of podophyllotoxin |
Country Status (10)
Country | Link |
---|---|
US (1) | US8940332B2 (zh) |
EP (1) | EP2019122A4 (zh) |
JP (1) | JP5181347B2 (zh) |
KR (1) | KR20090009241A (zh) |
CN (1) | CN101448875A (zh) |
AU (1) | AU2007252678A1 (zh) |
CA (1) | CA2652656A1 (zh) |
RU (1) | RU2447095C2 (zh) |
TW (1) | TW200811225A (zh) |
WO (1) | WO2007135910A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1792927B1 (en) * | 2004-09-22 | 2013-03-06 | Nippon Kayaku Kabushiki Kaisha | Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
JP5249016B2 (ja) | 2006-03-28 | 2013-07-31 | 日本化薬株式会社 | タキサン類の高分子結合体 |
RU2447095C2 (ru) | 2006-05-18 | 2012-04-10 | Ниппон Каяку Кабусики Кайся | Высокомолекулярный конъюгат подофиллотоксинов |
JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
JP5503872B2 (ja) | 2006-11-06 | 2014-05-28 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
WO2009116509A1 (ja) * | 2008-03-18 | 2009-09-24 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
JP5366940B2 (ja) * | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
CN102421827B (zh) | 2009-05-15 | 2014-07-30 | 日本化药株式会社 | 具有羟基的生理活性物质的高分子结合体 |
CN103221054A (zh) | 2010-11-17 | 2013-07-24 | 日本化药株式会社 | 新的胞苷类代谢拮抗剂的高分子衍生物 |
EP2754682B1 (en) | 2011-09-11 | 2017-06-07 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
CA2934863C (en) | 2014-01-10 | 2022-03-01 | Valinge Innovation Ab | Wood fibre based panel with a surface layer |
WO2015174909A1 (en) | 2014-05-12 | 2015-11-19 | Välinge Innovation AB | A method of producing a veneered element and such a veneered element |
EP3395857B1 (en) * | 2015-12-22 | 2021-05-26 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of sulfoxide derivative-coordinated platinum(ii) complex |
CN113797351B (zh) * | 2021-09-30 | 2023-10-27 | 大连民族大学 | 一步法合成pH响应型的靶向透明质酸-鬼臼毒素前药胶束及其应用 |
CN113750255B (zh) * | 2021-09-30 | 2023-10-31 | 大连民族大学 | 环境响应型透明质酸-鬼臼毒素前药胶束及其制备方法和应用 |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1467587A (en) * | 1974-07-11 | 1977-03-16 | Nestle Sa | Preparation of an asparagine or a glutamine |
JPS58135862U (ja) | 1982-03-10 | 1983-09-12 | 三洋電機株式会社 | 密閉型電池 |
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
JPS6296088A (ja) * | 1985-10-22 | 1987-05-02 | Kanebo Ltd | 抗腫瘍性物質の製法 |
US4734512A (en) * | 1985-12-05 | 1988-03-29 | Bristol-Myers Company | Intermediates for the production of podophyllotoxin and related compounds and processes for the preparation and use thereof |
CH667874A5 (fr) * | 1985-12-19 | 1988-11-15 | Battelle Memorial Institute | Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments. |
JPS6310789A (ja) | 1986-07-01 | 1988-01-18 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6323884A (ja) * | 1986-07-17 | 1988-02-01 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6461422A (en) * | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
JPS6461423A (en) * | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
US5182203A (en) * | 1989-03-29 | 1993-01-26 | E. I. Du Pont De Nemours And Company | Bifunctional compounds useful in catalyzed reporter deposition |
JP2517760B2 (ja) | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
JP3310000B2 (ja) | 1990-11-07 | 2002-07-29 | 靖久 桜井 | 水溶性高分子抗癌剤及び薬物担持用担体 |
JPH05117385A (ja) | 1991-10-31 | 1993-05-14 | Res Dev Corp Of Japan | ブロツク共重合体の製造法、ブロツク共重合体及び水溶性高分子抗癌剤 |
KR940003548U (ko) * | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
JP3270592B2 (ja) | 1992-10-26 | 2002-04-02 | 日本化薬株式会社 | ブロック共重合体−抗癌剤複合体医薬製剤 |
JP3268913B2 (ja) | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
JPH06206830A (ja) | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−薬剤複合体及び高分子ブロック共重合体 |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
US5985548A (en) * | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
DE4307114A1 (de) | 1993-03-06 | 1994-09-08 | Basf Ag | Verfahren zur Herstellung von Umsetzungsprodukten aus Polyasparaginsäureamid und Aminosäuren und ihre Verwendung |
JP2894923B2 (ja) | 1993-05-27 | 1999-05-24 | 日立造船株式会社 | ウォータージェット式双胴船のジェット水吸込口部構造 |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
JPH0848766A (ja) | 1994-05-30 | 1996-02-20 | Mitsui Toatsu Chem Inc | 重合体及びその製造方法 |
US5571889A (en) | 1994-05-30 | 1996-11-05 | Mitsui Toatsu Chemicals, Inc. | Polymer containing monomer units of chemically modified polyaspartic acids or their salts and process for preparing the same |
US5552517A (en) * | 1995-03-03 | 1996-09-03 | Monsanto Company | Production of polysuccinimide in an organic medium |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
PL189698B1 (pl) * | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
WO1997038727A1 (fr) | 1996-04-15 | 1997-10-23 | Asahi Kasei Kogyo Kabushiki Kaisha | Composite medicamenteux |
US5877205A (en) | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
BR9710366A (pt) | 1996-07-15 | 1999-08-17 | Yakult Honsha Kk | Derivados de taxane e drogas que os contêm |
AU729077B2 (en) | 1996-08-26 | 2001-01-25 | Transgene S.A. | Cationic lipid-nucleic acid complexes |
GB9625895D0 (en) * | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
DK0879604T3 (da) * | 1997-05-09 | 2003-08-04 | Deutsches Krebsforsch | Konjugat omfattende en folinsyreantagonist og en bærer |
WO1999030727A1 (en) | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
JPH11335267A (ja) | 1998-05-27 | 1999-12-07 | Nano Career Kk | 水難溶性薬物を含有するポリマーミセル系 |
IN191203B (zh) | 1999-02-17 | 2003-10-04 | Amarnath Prof Maitra | |
US6207832B1 (en) | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US20010041189A1 (en) * | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
ATE292965T1 (de) | 1999-09-14 | 2005-04-15 | Tepha Inc | Therapeutische anwendung von polymere die gamma- hydroxybutyrat enthalten |
US6376470B1 (en) | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
EP1466627A1 (en) | 1999-10-12 | 2004-10-13 | Cell Therapeutics, Inc. | Polyglutamate camptothecin conjugates |
US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
JP3523821B2 (ja) | 2000-02-09 | 2004-04-26 | ナノキャリア株式会社 | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
AU2001239275A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
TR200202194T2 (tr) | 2000-03-17 | 2003-01-21 | Cell Therapeutics, Inc. | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri |
US20020161062A1 (en) | 2001-11-06 | 2002-10-31 | Biermann Paul J. | Structure including a plurality of cells of cured resinous material, method of forming the structure and apparatus for forming the structure |
WO2001092584A1 (en) | 2000-06-02 | 2001-12-06 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
JP2002069184A (ja) | 2000-06-12 | 2002-03-08 | Mitsui Chemicals Inc | 重合体及びその製造方法 |
AU2001296215A1 (en) | 2000-07-17 | 2002-01-30 | Oxi-Gene, Inc. | Efficient method of synthesizing combretastatin a-4 prodrugs |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
ATE437647T1 (de) | 2001-02-16 | 2009-08-15 | Cellgate Inc | Transporter mit beabstandeten arginin-teilchen |
WO2002066066A1 (en) | 2001-02-20 | 2002-08-29 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
DK1362053T3 (da) | 2001-02-20 | 2008-03-10 | Enzon Inc | Terminalt forgrenede polymere linkere og polymere konjugater indeholdende disse |
KR100924990B1 (ko) | 2001-06-20 | 2009-11-04 | 니폰 가야꾸 가부시끼가이샤 | 불순물 함량을 감소시킨 블록 공중합체, 고분자 담체 및고분자 의약제제 및 그 제조 방법 |
CA2463902A1 (en) | 2001-10-26 | 2003-05-01 | Oxigene, Inc. | Functionalized stilbene derivatives as improved vascular targeting agents |
WO2003055860A1 (en) | 2001-12-21 | 2003-07-10 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
EP1487493B1 (en) * | 2002-03-01 | 2010-01-20 | The Administrators of The Tulane Educational Fund | Conjugates of cytotoxic agents and biologically active peptides |
CN100475269C (zh) | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
RS84904A (en) * | 2002-03-26 | 2006-12-15 | Bany Pharmaceutical Co.Ltd. | Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
JP2003342168A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
JP2003342167A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | カンプトテシン誘導体の製剤およびその調製方法 |
JP4270485B2 (ja) | 2002-05-28 | 2009-06-03 | 第一三共株式会社 | タキサン類の還元方法 |
JP2004010479A (ja) | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
US7495099B2 (en) | 2002-10-31 | 2009-02-24 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
US7169892B2 (en) * | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
MXPA05008335A (es) | 2003-02-11 | 2006-05-04 | Vernalis Cambridge Ltd | Compuestos de isoxazol como inhibidores de las proteinas de choque por calor. |
JP4757633B2 (ja) | 2003-03-20 | 2011-08-24 | 日本化薬株式会社 | 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 |
JP2006521367A (ja) | 2003-03-26 | 2006-09-21 | 株式会社Lttバイオファーマ | ターゲッティングと徐放を目的とした静脈注射用ナノ粒子 |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
JP2005051922A (ja) | 2003-07-29 | 2005-02-24 | Yokogawa Electric Corp | 電力供給システム及び電力供給方法 |
JPWO2005018674A1 (ja) | 2003-08-22 | 2006-10-19 | 協和醗酵工業株式会社 | イムノグロブリン遺伝子の転座を伴う疾患の治療薬 |
WO2005041865A2 (en) * | 2003-10-21 | 2005-05-12 | Igf Oncology, Llc | Compounds and method for treating cancer |
FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
US7176185B2 (en) * | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
EP2754454A3 (en) | 2004-01-07 | 2014-09-24 | Seikagaku Corporation | Non-steroidal anti-inflammatory drug derivatives |
EP1792927B1 (en) * | 2004-09-22 | 2013-03-06 | Nippon Kayaku Kabushiki Kaisha | Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
JP2006120914A (ja) | 2004-10-22 | 2006-05-11 | Matsushita Electric Ind Co Ltd | 部品吸着ノズル、並びに部品実装装置及び部品実装方法 |
CA2588124A1 (en) | 2004-11-16 | 2006-06-08 | Hyperion Catalysis International, Inc. | Method for preparing supported catalysts from metal loaded carbon nanotubes |
JP4954083B2 (ja) | 2004-11-18 | 2012-06-13 | シンタ ファーマスーティカルズ コーポレイション | Hsp90活性を調節するトリアゾール化合物 |
EP1857446B1 (en) | 2005-03-09 | 2013-05-01 | Nippon Kayaku Kabushiki Kaisha | Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer |
EP1857489A4 (en) * | 2005-03-09 | 2010-06-23 | Toray Industries | MICROPARTICLE AND PHARMACEUTICAL COMPOSITION |
US8399464B2 (en) * | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
WO2006115293A1 (ja) | 2005-04-22 | 2006-11-02 | The University Of Tokyo | pH応答性高分子ミセルの調製に用いる新規ブロック共重合体及びその製造法 |
CA2606939C (en) | 2005-05-11 | 2013-09-03 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of cytidine metabolic antagonist |
JPWO2006120915A1 (ja) | 2005-05-12 | 2008-12-18 | ニプロ株式会社 | 循環障害改善剤 |
EP2382995A3 (en) | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
JP4975297B2 (ja) | 2005-10-20 | 2012-07-11 | 山佐株式会社 | スロットマシン |
CN1800238A (zh) | 2005-12-05 | 2006-07-12 | 中国科学院长春应用化学研究所 | 有生物功能的脂肪族聚酯—聚氨基酸共聚物及合成方法 |
JP2007182407A (ja) | 2006-01-10 | 2007-07-19 | Medgel Corp | 徐放性ハイドロゲル製剤 |
JP2007191643A (ja) | 2006-01-20 | 2007-08-02 | Mitsui Chemicals Inc | 生体への定着性が付与されたポリアミノ酸誘導体 |
JP5249016B2 (ja) * | 2006-03-28 | 2013-07-31 | 日本化薬株式会社 | タキサン類の高分子結合体 |
RU2447095C2 (ru) | 2006-05-18 | 2012-04-10 | Ниппон Каяку Кабусики Кайся | Высокомолекулярный конъюгат подофиллотоксинов |
WO2008010463A1 (fr) | 2006-07-19 | 2008-01-24 | Nippon Kayaku Kabushiki Kaisha | Conjugué polymère d'une combrétastatine |
JP4587994B2 (ja) | 2006-08-10 | 2010-11-24 | 三菱電機株式会社 | 回路遮断器 |
JP5548364B2 (ja) | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
JP5503872B2 (ja) * | 2006-11-06 | 2014-05-28 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
US8188222B2 (en) * | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8703878B2 (en) * | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
WO2009116509A1 (ja) | 2008-03-18 | 2009-09-24 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
JP5366940B2 (ja) * | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
KR20110020779A (ko) * | 2008-05-23 | 2011-03-03 | 나노캐리어 가부시키가이샤 | 도세탁셀 고분자 유도체 및 그 제조 방법 및 그 용도 |
CN102421827B (zh) * | 2009-05-15 | 2014-07-30 | 日本化药株式会社 | 具有羟基的生理活性物质的高分子结合体 |
CN103221054A (zh) * | 2010-11-17 | 2013-07-24 | 日本化药株式会社 | 新的胞苷类代谢拮抗剂的高分子衍生物 |
-
2007
- 2007-05-16 RU RU2008149932/04A patent/RU2447095C2/ru not_active IP Right Cessation
- 2007-05-16 CN CNA2007800177809A patent/CN101448875A/zh active Pending
- 2007-05-16 AU AU2007252678A patent/AU2007252678A1/en not_active Abandoned
- 2007-05-16 KR KR1020087027893A patent/KR20090009241A/ko not_active Application Discontinuation
- 2007-05-16 WO PCT/JP2007/060026 patent/WO2007135910A1/ja active Application Filing
- 2007-05-16 CA CA002652656A patent/CA2652656A1/en not_active Abandoned
- 2007-05-16 EP EP07743461A patent/EP2019122A4/en not_active Withdrawn
- 2007-05-16 JP JP2008516621A patent/JP5181347B2/ja not_active Expired - Fee Related
- 2007-05-16 US US12/226,962 patent/US8940332B2/en not_active Expired - Fee Related
- 2007-05-17 TW TW096117516A patent/TW200811225A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2019122A1 (en) | 2009-01-28 |
JP5181347B2 (ja) | 2013-04-10 |
RU2447095C2 (ru) | 2012-04-10 |
EP2019122A4 (en) | 2009-07-01 |
AU2007252678A1 (en) | 2007-11-29 |
US20090162313A1 (en) | 2009-06-25 |
WO2007135910A1 (ja) | 2007-11-29 |
KR20090009241A (ko) | 2009-01-22 |
CN101448875A (zh) | 2009-06-03 |
RU2008149932A (ru) | 2010-06-27 |
JPWO2007135910A1 (ja) | 2009-10-01 |
CA2652656A1 (en) | 2007-11-29 |
US8940332B2 (en) | 2015-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200811225A (en) | Polymer conjugate of podophyllotoxin | |
TWI305538B (zh) | ||
JP5687899B2 (ja) | 生理活性物質の高分子結合体 | |
TW200813115A (en) | Polymer conjugate of combretastatin | |
JP5544357B2 (ja) | 水酸基を有する生理活性物質の高分子結合体 | |
TW200812572A (en) | Polymer conjugate of taxane | |
JP5349318B2 (ja) | ステロイド類の高分子結合体 | |
US20160279164A1 (en) | High-Molecular Weight Conjugate Of Resorcinol Derivatives | |
TW200836750A (en) | Polymeric derivative of nucleic acid metabolic antagonist | |
TW200836751A (en) | Polymeric derivative of nucleic acid metabolic antagonist | |
TW201601742A (zh) | 用於在活體中遞送RNAi觸發子至腫瘤細胞之聚結合物 | |
JPH07173080A (ja) | メトトレキセート誘導体とピラン共重合体の高分子結合体及びその製造方法 |